Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. SUPN | 0.00 |
Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:
SUPN) with a Overweight and raises the price target from $63 to $67.